IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024
IDEAYA Biosciences (NASDAQ: IDYA) has announced its virtual Investor R&D Day Webcast scheduled for December 16, 2024, from 8:00 am to 9:30 am ET. The event will showcase the company's precision medicine oncology pipeline, featuring presentations on multiple drug candidates including:
- IDE275/GSK959: Phase 1 Werner Helicase inhibitor
- IDE892: MTA-cooperative PMRT5 inhibitor
- IDE034: B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate
- A lysine acetyltransferase 6/7 development candidate
The agenda includes discussions on uveal melanoma treatment, tumor heterogeneity, and drug resistance. Distinguished speakers from institutions including Wills Eye Hospital, Dana-Farber Cancer Institute, and MD Anderson Cancer Center will participate. The presentation will be available on the company's website at 6:00 am ET.
IDEAYA Biosciences (NASDAQ: IDYA) ha annunciato il suo Investor R&D Day Webcast virtuale programmato per il 16 dicembre 2024, dalle 8:00 alle 9:30 ET. L'evento presenterà il pipeline di oncologia della medicina di precisione dell'azienda, con presentazioni su diversi candidati farmaceutici tra cui:
- IDE275/GSK959: inibitore della Werner Helicase di Fase 1
- IDE892: inibitore MTA-cooperante PMRT5
- IDE034: coniugato anticorpale bispecifico B7H3/PTK7 topo-I-payload
- Un candidato in sviluppo per l'acetiltransferasi della lisina 6/7
L'agenda include discussioni sul trattamento del melanoma uveale, eterogeneità tumorale e resistenza ai farmaci. Relatori distinti provenienti da istituzioni tra cui il Wills Eye Hospital, il Dana-Farber Cancer Institute e il MD Anderson Cancer Center parteciperanno. La presentazione sarà disponibile sul sito web dell'azienda alle 6:00 ET.
IDEAYA Biosciences (NASDAQ: IDYA) ha anunciado su Webcast virtual del Día del Inversor de I+D programado para el 16 de diciembre de 2024, de 8:00 a 9:30 a.m. ET. El evento mostrará la cartera de oncología de medicina de precisión de la compañía, presentando múltiples candidatos a fármacos, que incluyen:
- IDE275/GSK959: inhibidor de la Werner Helicase en Fase 1
- IDE892: inhibidor cooperativo de PMRT5 MTA
- IDE034: conjugado de anticuerpo bispecífico B7H3/PTK7 de topo-I-payload
- Un candidato en desarrollo para la acetiltransferasa de lisina 6/7
La agenda incluye discusiones sobre el tratamiento del melanoma uveal, heterogeneidad tumoral y resistencia a fármacos. Participarán oradores distinguidos de instituciones como el Wills Eye Hospital, el Dana-Farber Cancer Institute y el MD Anderson Cancer Center. La presentación estará disponible en el sitio web de la empresa a las 6:00 a.m. ET.
IDEAYA Biosciences (NASDAQ: IDYA)는 2024년 12월 16일 오전 8시부터 9시 30분(동부 표준시)까지 진행되는 가상 투자자 R&D 데이 웹캐스트를 발표했습니다. 이 행사는 회사의 정밀 의학 종양학 파이프라인을 소개하며, 다음과 같은 여러 약물 후보에 대한 발표가 포함됩니다:
- IDE275/GSK959: 1상 Werner Helicase 억제제
- IDE892: MTA 협동 PMRT5 억제제
- IDE034: B7H3/PTK7 topo-I-payload 이중특이성 항체 약물 접합체
- 리신 아세틸transferase 6/7 개발 후보
아젠다는 유분 멜라노마 치료, 종양 이질성 및 약물 저항성에 관한 논의를 포함합니다. Wills Eye Hospital, Dana-Farber Cancer Institute 및 MD Anderson Cancer Center의 저명한 연사들이 참여할 예정입니다. 발표는 오전 6시(동부 표준시)에 회사 웹사이트에서 확인할 수 있습니다.
IDEAYA Biosciences (NASDAQ: IDYA) a annoncé son Webcast virtuel du jour des investisseurs en R&D prévu pour le 16 décembre 2024, de 8h00 à 9h30 (heure de l’Est). L'événement mettra en avant le pipeline d'oncologie de la médecine de précision de l'entreprise, avec des présentations sur plusieurs candidats médicaments, notamment :
- IDE275/GSK959 : inhibiteur de la Werner Helicase de phase 1
- IDE892 : inhibiteur PMRT5 coopératif MTA
- IDE034 : conjuqué d'anticorps bispécifique B7H3/PTK7 topo-I-payload
- Un candidat en développement pour l'acétyltransférase de lysine 6/7
L'agenda inclut des discussions sur le traitement du mélanome uvéal, l'hétérogénéité tumorale et la résistance aux médicaments. Des intervenants distingués d'institutions telles que le Wills Eye Hospital, le Dana-Farber Cancer Institute et le MD Anderson Cancer Center participeront. La présentation sera disponible sur le site Web de l'entreprise à 6h00 (heure de l’Est).
IDEAYA Biosciences (NASDAQ: IDYA) hat seinen virtuellen Investor R&D Day Webcast für den 16. Dezember 2024, von 8:00 bis 9:30 Uhr ET, angekündigt. Die Veranstaltung wird das Onkologiepipeline der präzisen Medizin des Unternehmens präsentieren, einschließlich Präsentationen zu mehreren Arzneikandidaten, darunter:
- IDE275/GSK959: Phase-1-Werner-Helicase-Hemmer
- IDE892: MTA-kooperativer PMRT5-Hemmer
- IDE034: B7H3/PTK7-Topo-I-Payload-bispezifischer Antikörper-Wirkstoffkonjugat
- Ein Entwicklungsprojekt für Lysacetyltransferase 6/7
Die Agenda umfasst Diskussionen über die Behandlung von uvealem Melanom, Tumorheterogenität und Arzneimittelresistenz. Angesehene Redner von Institutionen wie dem Wills Eye Hospital, dem Dana-Farber Cancer Institute und dem MD Anderson Cancer Center werden teilnehmen. Die Präsentation wird um 6:00 Uhr ET auf der Website des Unternehmens verfügbar sein.
- Multiple potential first-in-class drug candidates in development pipeline
- Strategic partnership with GSK for Werner Helicase program
- Distinguished panel of medical experts and key opinion leaders participating
- None.
The presentations by IDEAYA management and key opinion leaders will showcase scientific insights and clinical development opportunities across IDEAYA's precision medicine oncology pipeline. In addition, IDEAYA will highlight its next-generation precision medicine pipeline programs, including IDE275 / GSK959, a potential first-in-class and best-in-class Phase 1 Werner Helicase inhibitor, IDE892, a potential best-in-class MTA-cooperative PMRT5 inhibitor, IDE034, a potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC), and a potential first-in-class lysine acetyltransferase 6/7 (KAT6/7) development candidate.
The IDEAYA Investor R&D Day Webcast agenda will be the following:
Agenda Topics
- Building Global Leader in Precision Medicine Oncology
- IDEAYA Vision & Strategy
- Uveal Melanoma Roundtable
- Treatment Paradigms in Neoadjuvant Uveal Melanoma
- New Paradigms to Address Tumor Heterogeneity and Drug Resistance
- Mechanistic Rationale Underpinning IDE161/Keytruda and IDE161/ADC Combination Opportunities
- IDEAYA and GSK Partnership
- IDE275 / GSK959 (Phase 1) Werner Helicase Program Update by GSK
- Development Candidate Updates
- IDE892 (PRMT5), IDE034 (B7H3/PTK7 Bispecific Topo ADC), and KAT6/7 Development Candidates
R&D Day Guest Speakers
- Carol Shields, M.D., Chief, Ocular Oncology Service at Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University
- Amy Schefler, M.D., Partner at Retina Consultants of
Texas , and Clinical Associate Professor at Weill Cornell Medical College, Houston Methodist Hospital and University of Texas Health Science Center atHouston - Kornelia Polyak, M.D., Ph.D., Professor of Medicine at Dana-Farber Cancer Institute (DFCI), Harvard Medical School, a co-leader of the Cancer Cell Biology Program at the Dana-Farber Harvard Cancer Center, and a member of the National Academy of Sciences and the National Academy of Medicine
- Timothy Yap, MBBS, Ph.D., Professor, Department for Investigational Cancer Therapeutics and Department of Thoracic/Head and Neck Medical Oncology, Medical Director, Institute for Applied Cancer Science, Associate Director of Translational Research, Khalifa Institute for Personalized Cancer Therapy, M.D. Anderson Cancer Center
- Ramon Kemp, Ph.D., Vice President, Head, Oncology EDL, GSK
Investor R&D Day Webcast Presentation and Registration Information
IDEAYA's Investor R&D Day webcast presentation will be available on the company's website, at its Investor Relations portal (https://ir.ideayabio.com/) in advance of the investor webcast presentation at approximately 6:00 am ET.
Registration is available at https://ir.ideayabio.com/events or https://lifescievents.com/event/ideaya-4/.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, (i) statements related to participation in, presentation at, and/or content of IDEAYA's Investor R&D Day (ii) clinical development opportunities across IDEAYA's precision medicine oncology pipeline; and (iii) the potential therapeutic opportunities of IDEAYA's pipeline programs, including treatment for uveal melanoma, new paradigms to address tumor heterogeneity and drug resistance, the IDE161/Keytruda and IDE161/ADC combinations, and the IDE275 / GSK959 (Werner Helicase Program); and IDE892 (a MTA-cooperative PMRT5 inhibitor), IDE034 (a B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC), and a lysine acetyltransferase 6/7 (KAT 6/7) development candidates. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Quarterly Report on Form 10-K filed on February 20, 2024 and any current and periodic reports filed with the
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-announces-agenda-for-investor-rd-day-webcast-on-december-16-2024-302328702.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
When is IDEAYA Biosciences (IDYA) hosting its Investor R&D Day Webcast in December 2024?
What are the main drug candidates IDYA will discuss during its R&D Day?
How can investors access IDEAYA's (IDYA) R&D Day presentation materials?
Who are the key speakers participating in IDYA's R&D Day event?
